NASDAQ:CPRX Catalyst Pharmaceuticals Q1 2025 Earnings Report $24.28 +0.65 (+2.75%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$24.50 +0.22 (+0.93%) As of 04/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Catalyst Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.53Beat/MissN/AOne Year Ago EPSN/ACatalyst Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$130.86 millionBeat/MissN/AYoY Revenue GrowthN/ACatalyst Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/7/2025TimeAfter Market ClosesConference Call DateThursday, May 8, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Catalyst Pharmaceuticals Earnings HeadlinesCatalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy NowApril 27 at 7:31 PM | msn.comCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025April 22, 2025 | globenewswire.comTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.April 30, 2025 | Timothy Sykes (Ad)Catalyst Pharmaceuticals price target raised to $34 from $33 at BofAApril 22, 2025 | markets.businessinsider.comCiti Remains a Buy on Catalyst Pharma (CPRX)April 18, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gainsApril 17, 2025 | marketwatch.comSee More Catalyst Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email. Email Address About Catalyst PharmaceuticalsCatalyst Pharmaceuticals (NASDAQ:CPRX), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.View Catalyst Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Upcoming Earnings Monster Beverage (5/1/2025)Airbnb (5/1/2025)Amazon.com (5/1/2025)Apple (5/1/2025)Atlassian (5/1/2025)Amgen (5/1/2025)Strategy (5/1/2025)Linde (5/1/2025)MercadoLibre (5/1/2025)ING Groep (5/1/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
